Lapahope 250mg
Lapahope 150mg tablets are classified as an anti-cancer agent, which is an orally active drug used for treating breast cancer.Chemically classified as quinazoline with strong anti-cancer effect and the tablet Lapahope 150mg tablet is a synthetic oral tablet.
Normally targeted therapy or tyrosine kinase inhibitor drugs can increase the plasma amino transferase levels which may lead to liver injury.
Lapahope 150mg tablets are classified as;
1.Tyrosine kinase prohibition
2. Stop the HER2/neu & epidermal growth factor receptor activity
3.Targeted therapy
4.Signal transduction prohibition.
INDICATION
Primarily Lapahope 150mg indicated for advanced breast cancer.Lapahope 150mg is indicated for the combination with Capecitabine tablets are normally indicated for the treatment of metastatic breast cancer patients in whose cancer cells expressed with EGFR 2 (HER2) and already patients may get an anthracycline, taxane & Trastuzumab.
 |
| lapahope 150mg,lapahope 150mg tablet |
DOSAGE
In HER2 positive advanced breast cancer:
The usual dose of Lapahope is 1250mg should be given orally as a single dose on day 1 to 21 repeatedly concomitant with Capecitabine 2000mg/m2/day (administer 2 doses relatively 12 hours apart orally) on day 1 to 14 in a continuous 21-day cycle.Sum of 5 tablets of Lapahope should be given at a time as a whole.
Patients with hormone receptor-positive HER 2 positive advanced breast cancer:
The usual dose is 1500mg should be given orally as a single dose by combination with letrozole.
The usual dose of letrozole is 2.5mg as a once daily
Administer 6 tablets of Lapahope in this condition Dose alteration:
Cardiac events:
Left ventricular ejection fraction with grade 2 reduction in patients is given treatment with Lapahope should be discontinued.In this condition, the dose of Lapahope should be started with 1000mg/day in combining with Capecitabine; whereas in combination with letrozole the dose of Lapahope restated with 1250mg/day after 2 weeks, if LVEF turns to normal.
Hepatic impairment:
Severe hepatic impairment in patients, the dose reduced from 1250mg/day to 750mg/day or from 1500mg/day to 1000mg/day.Administer the Lapahope tablet without food as 1 hour before or 2 hours after the uptake of food.
PHARMACOLOGY
Chemically Lapahope 150mg is classified as 4-anilinoquinazoline derivative, that evacuates anti-cancer activity by inhibiting intracellular tyrosine kinase domains of EFGR & HER type 2. The ErbB forced cancer cell production has been prevented by Lapatinib.This growth factor receptor present on the cell surface of cancer mass which may lead to cause cell death.
Absorption :
Incomplete and insufficient absorption, the time to peak plasma concentration is 4 hours after intake of the drug.Distribution :
The drug bounds to human plasma protein like albumin & alpha glycoprotein relatively 99%.Metabolism :
Lapahope is a substrate of P-gp& BCRP and goes through intensive metabolism by using CYPP3A4 & CYP3A5 with a minimum contribution of CYP2C19 & CYP2C8.Excretion :
Elimination occurs via feces & urine.
Half-life time in 14.2 hours reaches by a single dose of Lapahope 150mg and multiple dosing reaches in 24 hours.
PRECAUTION
Reduction in left ventricular ejection fraction:
While using Lapahope 150mg in a patient with LVEF Caution should be takenThe resentment of LVEF should be decreased within the first 12 weeks of treatment
Before starting the therapy with Lapahope, patient must be monitor thoroughly if suspected with LVEF or not.
Liver damage:
Raising the level of AST, ALT or bilirubin may cause liver injuryTo inhibits this condition, periodic LFT should be control
Diarrhea:
Serious diarrhea may cause to dehydration leads death also; if the patient does not recover from this severity must stop with this therapy.Interstitial lung disease:
The patient should be check with pulmonary symptoms and give supportive measures.On Serious condition, treatment should be discontinuing
QT prolongation:
Balance ECG periodicallyGive the patient substituent for this adverse condition
Hypokalemia and hypomagnesemia correction should take place
Cutaneous reactions:
Some life-threatening reactions may occur, in this condition, therapy should be discontinuedEmbryo fetal damage:
Lapahope leads to fetal damage and produces some deformities.During therapy Patient should advice not getting pregnant
DRUG INTERACTION
The drug Lapahope 150mg is the prohibition of CYP3A4, CYP2C8 & P-gp drug transporters; a weak inhibitor of CYP3A4.Interaction of Midazolam with Lapahope 150mg increases the exposure of Midazolam
Interaction of Paclitaxel Will Increase in paclitaxel exposure occurs while concomitant with Lapahope.
Digoxin interaction with Lapahope then the Serum digoxin concentration should be examined periodically prior starting the concomitant use.
Drug that induce or inhibit CYP3A4 enzymes:
If the interaction of Lapahope tablets with CYP3A4 inducers or inhibitors, alteration of the dose is necessary.
Interaction of Ketoconazole with Lapahope 150mg, the dose reduced to 200mg as two times a day for 7 days.
Interaction of Carbamazepine with Lapahope, the dose of carbamazepine at 100mg as two times a day for 3 days & 200mg for two times a day for 17 days, the exposure of Lapahope reduced to 72%.
Concomitant use of Lapahope with P-gp inhibitors causes increasing the concentration of Lapatinib.
CONTRAINDICATION
The patients who are contraindicated to the component present in Lapahope 150mg tablet then Hypersensitivity reaction occurs.Contact Details
Phone : +91-9987711567
Email :applepharmaceutical@gmail.com
Email :info@myapplepharma.com
Comments
Post a Comment